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Objective: ANTHEM-HF evaluated a novel autonomic regulation therapy (ART) via either left or right
vagus nerve stimulation (VNS) in patients with heart failure (HF) and reduced ejection fraction (HFrEF).
Methods and Results: Sixty subjects (New York Heart Association [NYHA] functional class IIeIII, left
ventricular ejection fraction (LVEF) #40%, left ventricular end-diastolic diameter $50 mm to!80 mm)
receiving optimal pharmacologic therapy were randomized at 10 sites. VNS systems were randomly im-
planted on the left (n 5 31) or right (n 5 29) side. All patients were successfully implanted and 59 were
titrated over 10 weeks to a well tolerated stimulation intensity. One patient died 3 days after an embolic
stroke that occurred during implantation. Common device-related adverse events after VNS titration were
transient mild dysphonia, cough, and oropharyngeal pain, which were similar for left- and right-side VNS.
After 6 months of ART, the adjusted left-right differences in LVEF, left ventricular end-systolic volume
(LVESV), and left ventricular end-systolic diameter (LVESD) were 0.2% (95% CI -4.4 to 4.7), 3.7 mL
(95% CI -7.0 to 14.4), and 1.3 mm (95% CI -0.9 to 3.6), respectively. In the combined population, absolute
LVEF improved by 4.5% (95% CI 2.4e6.6), LVESV improved by -4.1 mL (95% CI -9.0 to 0.8), and
LVESD improved by -1.7 mm (95% CI -2.8 to -0.7). Heart rate variability improved by 17 ms (95%
CI 6.5e28) with minimal left-right difference. Six-minute walk distance improved an average of 56 m
(95% CI 37e75); however, improvement was greater for right-side ART (77 m [95% CI 49-105]).
NYHA functional class improved in 77% of patients (baseline to 6 months).
Conclusions: Chronic open-loop ART via left- or right-side VNS is feasible and well tolerated in HFrEF pa-
tients. Safety and efficacy measures are encouraging and warrant further study. (J Cardiac Fail
2014;20:808e816)
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therapy.Patients with chronic heart failure (HF) have features of
autonomic dysfunction characterized by excessive sympa-
thetic activation and concomitant parasympathetic with-
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of pharmacologic therapy and devices, the overall prog-
nosis of HF patients remains poor and new therapies are
needed.5
In response to a cardiac insult, the autonomic nervous
system attempts to preserve cardiac output by up-
regulating sympathetic activity and withdrawing parasym-
pathetic activity. These changes in autonomic regulatory
control of the cardiovascular system lead to a host of
pathophysiologic changes, including excessive adrenergic
receptor system activation, with long-term deleterious
consequences. It has been hypothesized that electrical stim-
ulation of the vagus nerve may normalize parasympathetic
activation of cardiac control reflexes and inhibit sympa-
thetic hyperactivation known to be associated with chronic
HF and reduced ejection fraction (HFrEF).6e10
Vagus nerve stimulation (VNS) has been used clinically
for O25 years, and its safety profile has been well
established in patients with refractory epilepsy and
depression.11e13 In a variety of acute and chronic non-
human animal models, VNS has been shown to reduce
vulnerability to ventricular arrhythmias, attenuate infarct
size, and reduce mortality.8,9,14e16 Recent animal studies
have evaluated autonomic regulation therapy (ART) with
VNS in HF and demonstrated sustained improvement in
cardiac function and HF symptoms.17e20 ART feasibility
and tolerability was first evaluated in a 32-patient open-
label clinical study, which showed that stimulation pulses
(5.5 mA target), delivered to the right vagus nerve and syn-
chronized to the cardiac cycle, were associated with a sig-
nificant improvement in cardiac function, as measured by
left ventricular ejection fraction (LVEF), left ventricular
end-systolic volume (LVESV), quality of life, and exercise
performance.21
Although ART has been more widely studied through
stimulation of the right vagus nerve,17e23 there is experi-
mental evidence to suggest that left-side stimulation also
has therapeutic benefits in the setting of cardiac dysfunc-
tion.16,24 ART as an HF therapy on the left side may have
advantages, allowing the therapy to be combined with
cardiac devices such as implantable cardioverter-
defibrillators (ICDs) and cardiac resynchronization therapy
(CRT) devices, the vast majority of which are implanted on
the left side of the thorax. The feasibility and tolerability of
left-side VNS is well established in epilepsy patients11e13;
however, left-side VNS has not been evaluated in HF pa-
tients, and the effects of left- and right-side VNS have
not been directly compared.
The Autonomic Neural Regulation Therapy to Enhance
Myocardial Function in Heart Failure (ANTHEM-HF)
study is a multicenter open-label feasibility study designed
to assess the safety, tolerability, and efficacy of a new
approach to ART in patients with chronic, stable, symptom-
atic HFrEF, and to compare the effects of right- and
left-side VNS. In contrast with the previously reported
feasibility study,21 ANTHEM-HF evaluated the effects of
continuous cyclic stimulation applied to the vagus nerve
at an amplitude of 1.5e3.0 mA and a constant frequencyof 10 Hz. The study assessed whether the therapy improves
LV structure and function and reduces symptom burden in
patients with chronic stable HF.
Methods
Study Design
The ANTHEM-HF study design was published previously.25
Briefly, 60 subjects in New York Heart Association (NYHA) func-
tional class IIeIII HF, age $18 years, were enrolled at 10 sites in
India over 13 months (July 2012 to July 2013). Inclusion criteria
included LVEF #40%, LV end-diastolic diameter 50 mm to
!80 mm, QRS width #150 ms, and receiving optimal medical
management, including stable b-blocker therapy for HF as indi-
cated and tolerated for $3 months and all other oral pharmaco-
logic therapy for HF, including angiotensin-converting enzyme
(ACE) inhibitors or angiotensin receptor blockers (ARBs), loop
diuretics, and spironolactone, for $1 month. Patients were also
required to be physically capable of performing the 6-minute
walk test (6MWT) with a baseline distance of 150e425 m, as
limited by HF symptoms.
Objectives
The main objective of ANTHEM-HF was to evaluate the safety
and efficacy of ART for the treatment of patients with chronic
symptomatic HFrEF. The study also evaluated ART system perfor-
mance by assessing feasibility, the percentage of randomized pa-
tients who were successfully implanted with the device, and
tolerability, the ability to maintain therapy throughout the
6-month follow-up period after the tolerable level of stimulation
was determined during the 10-week titration period.
The primary safety endpoint was the incidence of procedure and
device-related adverse events. The primary efficacy endpoints
were changes in LVEF and LVESV at 6 month. The secondary
exploratory endpoints included left ventricular end-systolic diam-
eter (LVESD), NYHA functional class; 6MWT, Minnesota Living
with Heart Failure Questionnaire (MLHFQ), mean HR and HR
variability during 24-h Holter electrocardiography (ECG), and
plasma biomarkers, including N-terminal proeB-type natriuretic
peptide (NT-proBNP) and high-sensitivity C-reactive protein
(hs-CRP). All outcome measurements were made at baseline
and 3 and 6 months after VNS titration.
System Implantation and ART Implementation
Subjects fulfilling the inclusion and exclusion criteria were ran-
domized 1:1 to receive VNS Therapy System implantation (Demi-
pulse Model 103 pulse generator and PerenniaFLEX Model 304
lead; Cyberonics, Houston, Texas) with lead placement on either
the right or left cervical vagus nerve. The pulse generator was acti-
vated 15 6 3 days after implantation. All patients were initially
stimulated at a pulse width of 130 ms and a pulse frequency of
10 Hz, continuous cyclic 14 s active (on) and 66 s inactive (off;
1,080 cycles/d). Stimulation parameters were systematically
adjusted during periodic clinic visits over a 10-week titration period
to a pulse width of 250 ms, a pulse frequency of 10 Hz, and target
output current amplitude of 1.5e3.0 mA. VNS activation and inac-
tivation periods were unrelated to the cardiac cycle (ie, open loop),
so no intracardiac sensing lead was used. During titration sessions,
VNS intensity was gradually increased in 0.25-mA steps with the
use of a radiofrequency programmer (Model 250 programming sys-
tem; Cyberonics) to levels that produced acute VNS-related side
Fig. 1. Flowchart of patient progress through study phases. One
patient who was randomized to receive a right-side implant
received a left-side implant based on physician judgment. F/U,
follow-up.
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tory reflex (mild cough) or modest HR reduction. When the VNS
tolerance zone boundary was established by evidence of expiratory
reflex activation or HR reduction, the output current was reduced by
$1 output current step (0.25 mA) to insure that the therapy was
well tolerated. During all titration sessions, lead II ECG was contin-
uously monitored (Model MP150 Data Acquisition System; Biopac
Systems, Goleta, California) to provide baseline HR (30-s average)
along with real-time HR (3-beat average) to determine HR effects
associated with VNS and confirm that acute HR change did not
exceed 4e6 beats/min.
Echocardiographic and Safety Adjudication
All transthoracic echocardiographic recordings and blood sam-
ples were deidentified of patient and sample information and sent
to designated core laboratory facilities (echocardiography: Care
Hospital, Hyderabad, India; blood: Metropolis Healthcare, Mumbai,
India) for blinded analysis. The investigators did not have access to
the core laboratory (echocardiography or blood) results. The study
was overseen by an independent Data Safety and Monitoring Com-
mittee (Appendix). All adverse events were documented by study
investigators and adjudicated by an independent Clinical Events
Adjudication Committee (Appendix), which determined whether
events were related or unrelated to the therapy system being evalu-
ated after thoroughly reviewing patient records and investigator nar-
ratives. Adverse events were further adjudicated as being related or
unrelated to implantation or stimulation.
Statistical Analysis
Continuous variables are described by mean and SD or median
(interquartile range [IQR]) for skewed distributions. Left-versus
right-side differences in 6-month changes in efficacy variables
were estimated with the use of linear regression (Stata v13.1 soft-
ware). Baseline values of the change variable were included in the
regression models of 6-month changes to help control for regres-
sion to mean. In addition, the left-versus right-side comparisons
were adjusted for ischemic etiology, baseline HR, and HF medica-
tions, including ACE inhibitor or ARB, loop diuretic, spironolac-
tone, and digoxin. All subjects (100%) were on a beta-blocker.
The average changes after 3 months (Supplemental Table 2)
were nearly equal to the changes after 6-months, so 1 echocardi-
ography and 2 HR variability 3-month values were carried forward
to fill in missing 6-month values; carry-forward analysis had no
material effect on computed values. Three subjects died before
the 3-month follow-up. Marginal (adjusted) means are reported
with 95% confidence intervals (CIs) for the left, right, and
combined treatment groups. One subject who was randomized to
treatment on the right side was treated on the left side based on
the investigator’s judgment, and was included in the left-side treat-
ment group.
The study complied with the Declaration of Helsinki. The study
protocol was approved by local Ethics Committees at all sites, and
all patients gave written informed consents translated into local
languages.
Results
Baseline Characteristics of Patients
Patient enrollment and follow-up are summarized in
Figure 1. All 60 randomized patients were successfully
implanted with a pulse generator and lead system. Onepatient who was randomized to receive a right-side
implant received a left-side implant based on physician
judgment. This approved protocol deviation was not due
to lack of feasibility of right-side implantation. The base-
line characteristics of the randomized patients are summa-
rized in Table 1. All patients (n 5 60) were NYHA
functional class II (57%) or III (43%), with an average
LVEF of 32 6 7%. The average LVESD and LVEDD
were 51.6 6 7.9 mm and 61.7 6 6.7 mm, respectively, un-
corrected for a mean body surface area of 1.66 6 0.15 m2.
Patients received optimal pharmacologic therapy for HF,
with 100% receiving beta-blocker therapy and 85%
receiving ACE inhibitor or ARB therapy. Medication
changes were permitted according to physician judgment;
however, there were no significant changes in HF medica-
tions during the study.
Heart failure etiology was ischemic in 75% of patients,
and 33% of patients had mitral regurgitation (grade $1).
Five patients had mitral regurgitation grade $3. Baseline
median NT-proBNP (868 pg/mL, IQR 322e1,875 pg/mL)
was elevated. None of the patients had an ICD or CRT de-
vice at enrollment. The baseline characteristics of patients
randomly implanted on the left or right side were similar
except for ischemic etiology and use of HF medications.
Titration and Tolerance of Stimulation
During the titration period (10 6 2 visits), the tolerance
zone boundary increased in all patients, allowing for
progressive increase in VNS intensity. At the end of the
10-week titration period, the average up-titrated output cur-
rent in 59 patients was 2.0 6 0.6 mA (right side:
1.7 6 0.5 mA; left side: 2.2 6 0.5 mA). Of the 59 patients,
Table 1. Baseline Characteristics of Enrolled Patients
Left (n 5 31) Right (n 5 29) Overall (n 5 60)
Demographics
Age (y) 51.2 6 12.4 51.9 6 12.4 51.5 6 12.2
Male (%) 87 86 87
Medical history
Duration of HF (y) 3.7 6 3.9 3.9 6 4.7 3.8 6 4.3
Heart failure etiology (%)
Ischemic 68 83 75
Nonischemic 32 17 25
Clinical examination
NYHA II/III 18/13 16/13 34/26
MLHFQ score 38 6 15 41 6 11 40 6 14
Body mass index (kg/m2) 24.0 6 3.5 24.2 6 4.7 24.1 6 4.1
LVEF (%) 32.8 6 8.0 31.9 6 6.4 32.4 6 7.2
LVESV (mL) 109.1 6 40.8 106.6 6 40.1 107.9 6 40.1
LVESD (mm) 51.5 6 7.4 51.6 6 8.6 51.6 6 7.9
LVEDD (mm) 61.7 6 6.7 62.2 6 7.1 61.7 6 6.7
HR (beats/min) 78 6 11 77 6 10 78 6 10
Systolic BP (mm Hg) 114 6 14 112 6 15 113 6 15
Diastolic BP (mm Hg) 73 6 8 74 6 10 73 6 9
6MWT (m) 291 6 60 282 6 73 287 6 66
QRS width (ms) 98 6 32 95 6 30 96 6 31
Clinical chemistry
Creatinine (mg/dL) 1.1 6 0.4 1.0 6 0.3 1.1 6 0.3
eGFR (mL min1 1.73 m2) 87 6 36 94 6 38 90 6 37
NT-proBNP (pg/mL), median (IQR) 864 (322e1,788) 874 (324e2,101) 868 (322e1,875)
CRP (mg/dL), median (IQR) 1.9 (1.0e7.2) 1.6 (0.8e3.8) 1.7 (0.9e6.0)
Heart failure drug treatment (%)
b-blocker 100 100 100
ACE-I or ARB 83 87 85
Aldosterone antagonist 71 79 75
Digoxin 39 24 32
Loop diuretics 97 79 88
ICD use (n)
Implanted before randomization 0 0 0
Implanted during the study period 0 2 2
HF, heart failure; NYHA, New York Heart Association functional class; MLHFQ, Minnesota Living with Heart Failure Questionnaire; LVEF, left ventric-
ular ejection fraction; LVESV, left ventricular end-systolic volume; LVESD, left ventricular end-systolic diameter; LVEDD, left ventricular end-diastolic
volume; HR, heart rate; BP, blood pressure; 6MWT, 6-minute walk test; eGFR, estimated glomerular filtration rate; NT-proBNP, N-terminal pro-B-type natri-
uretic peptide; CRP, C-reactive protein; ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ICD, implantable cardioverter-
defibrillator.
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cough, voice alteration, sensation of stimulation) in 50 pa-
tients, by maximum current amplitude of 3.0 mA in 5, and
by acute HR change in 4. In these 4 patients, an HR reduc-
tion of 3e5 beats/min was seen during the VNS ‘‘on’’ time
at the end of the titration period, and further increase in in-
tensity would have decreased their HR even more. At the
end of each titration session, no patients were programmed
to a VNS intensity that elicited side effects or an acute HR
reduction of O4e6 beats/min.
Continuous cyclic stimulation was maintained at a toler-
able level throughout the titration period and the 6-month
follow-up period. None of the patients or investigators re-
quested discontinuation of ART during the study, and
none of the patients used the magnet to temporarily inhibit
stimulation, suggesting that therapy was tolerable
throughout the study period. At the end of the 6-month
follow-up period, the average output current in 57 patients
was 2.0 6 0.6 mA (right side: 1.7 6 0.5 mA; left side:
2.3 6 0.6 mA). After completion of the ANTHEM-HFstudy, patients are being followed in a separate extension
study for an additional 12 months.Safety Assessment
Table 2 summarizes the adverse events. During the study,
continuous cyclic stimulation was delivered for a cumula-
tive 43 patient-years. A total of 21 serious adverse events
(SAEs) occurred in 16 patients (Supplemental Table 1).
Of these SAEs, 1 was related to the ART system: a death
due to an embolic stroke that occurred 3 days after surgery
in a patient who had extensive atherosclerosis of the carotid
arteries and that was adjudicated to be implantation proce-
dure related.
The remaining 20 SAEs were adjudicated to be unrelated
to the ART system. There were 2 other deaths during the
study that occurred after the titration period but before
the 3-month follow-up visit: 1 sudden cardiac death and
1 due to worsening HF related to HF medication noncom-
pliance. Both patients had left-side VNS, and the events
Table 2. Adverse Events (AEs)
Left Right Overall
Serious AEs (SAEs) 10 11 21
Related 1 0 1
Unrelated 9 11 20
Related SAEs
Death (embolic stroke) 1 0 1
Unrelated SAEs
Death (sudden death) 1 0 1
Death (heart failure) 1 0 1
HF hospitalization 3 3 6
Unstable angina 0 2 2
Ventricular tachycardia 0 2 2
Bone fracture 1 0 1
Cataract 0 1 1
Dengue fever 0 1 1
Hernia 1 0 1
Pneumonia 0 1 1
Stroke 1 0 1
Urine retention 1 0 1
Weight loss 0 1 1
Other related AEs 82 91 173
Most common related AEs
Dysphonia 11 8 19
Cough 6 7 13
Oropharyngeal pain 4 4 8
Device malfunctions 0 0 0
Fig. 2. Mean and 95% confidence intervals of echocardiographic
changes after 6 months of autonomic regulation therapy (overall,
left-side treatment, and right-side treatment). LVEF, left ventricu-
lar ejection fraction; LVESV, left ventricular end-systolic volume;
LVESD, left ventricular end-systolic diameter.
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apy. Thus, the overall mortality in this study was 3/60 (5%),
consistent with the severity of HF in this patient
cohort,26e28 and the mortality rate attributed to the therapy
over the 9-month study period, from implantation to final
follow-up, was 1/60 (1.7%).
There were 173 device-related nonserious adverse events
(AEs); 82 AEs were reported in the group receiving left-
side VNS and 91 were reported in the group receiving
right-side VNS. Among the 82 AEs that occurred in the
group receiving left-side VNS, 34 were implantation
related and 48 were stimulation related. Among the 91
AEs that occurred in the group receiving right-side VNS,
37 were implantation related and 54 were stimulation
related. The most common nonserious AEs (Table 2)
were mild dysphonia (19), cough (13), and oropharyngeal
pain (8). The most common procedure-related side effects
were transient dysphonia and oropharyngeal pain at the
implant site. The most common stimulation-related side
effects were transient mild dysphonia and cough, limited
to the active phase of ART. Stimulation-related AEs were
transient, could be ameliorated with adjustment of stimula-
tion parameters, and subsided over time. Most AEs (93%)
occurred between implant and end-titration. All device-
related AEs resolved without consequence. There were no
device-related infections or malfunctions, no unexpected
device-related adverse events, and no patients who discon-
tinued therapy during the study.
An exploratory analysis of the 24-hour Holter monitoring
records demonstrated an average decrease in mean HR of
3.9 6 9.8 beats/min from baseline to 6 months (right
side: 4.3 beats/min; left side: 3.4 beats/min). Investigator
review of the Holter records did not reveal any clinicallysignificant changes in atrial or ventricular ectopic activity,
no increase in bradycardia or tachycardia events, and no
new-onset atrial fibrillation. However, 2 patients received
an ICD during the study after presenting with ventricular
tachycardia. Both of these patients had received right-side
VNS, and these events were adjudicated to be unrelated
to the therapy. In these 2 patients implanted with ICDs dur-
ing the study, there was no device interaction between the
ICD and the ART systems.Efficacy Assessments
Echocardiographic measures are presented in Figure 2
and Table 3. After the 6-month study period, the observed
mean (95% CI) differences between the left and right treat-
ment groups in changes in LVEF, LVESV, and LVESD were
0.2% (-4.4 to 4.7), 3.7 mL (-7.0 to 14.4), and 1.3 mm (-0.9
to 3.6), respectively. After pooling the left- and right-side
data, the average estimated increase in LVEF was 4.5%
[2.4 to 6.6]. LVESV decreased by -4.1 mL [-9.0 to 0.8],
and LVESD decreased by -1.7 mm [-2.8 to -0.7].
Heart rate variability (SD of normal to normal intervals)
also improved in the pooled sample by 17 ms (95% CI
6.5e28) with relatively little left-right difference
(Table 3). Changes in NT-proBNP levels were highly vari-
able, with wide, inconclusive confidence intervals. CRP
significantly decreased in the pooled sample by 2.9 mg/
dL on average with relatively small left-right difference.
Renal function, as measured by estimated glomerular filtra-
tion rate, did not change. BNP, angiotensin II, and norepi-
nephrine levels also did not change over the 6-month
study period (data not shown).
The NYHA functional class of 77% of patients improved
from baseline to the 6-month follow-up visit. No patients
showed worsening NYHA functional class at 6 months.
Measurements of patient functional status and quality of
life are presented in Table 3. The improvement in the
6-minute walk distance over the 6-month study period
was significantly less with left-side VNS (-43 m [95%
Table 3. Efficacy Measures
Left Treatment Right Treatment LefteRight Difference* Combined
LVEF (%) 4.6 (1.5 to 7.7) 4.4 (1.3 to 7.5) 0.2 (4.4 to 4.7) 4.5 (2.4 to 6.6)
LVESV (mL) -2.2 (9.5 to 5.1) -5.9 (13.1 to 1.2) 3.7 (7.0 to 14.4) -4.1 (9.0 to 0.8)
LVESD (mm) -1.1 (2.6 to 0.5) -2.4 (3.9 to 0.9) 1.3 (0.9 to 3.6) -1.7 (2.8 to 0.7)
6MWT (m) 34 (5.4 to 62) 77 (49 to 105) -43 (85 to 1.3) 56 (37 to 75)
MLHFQ -17 (20 to 13) -20 (24 to 17) 3.6 (1.8 to 8.8) -18 (21 to 16)
Holter HR (beats/min) -3.4 (7.0 to 0.2) -4.3 (7.9 to 0.8) 0.9 (4.4 to 6.2) -3.9 (6.3 to 1.5)
SDNN (ms) 20 (4.6 to 36) 14 (1.8 to 30) 6.3 (17 to 30) 17 (6.5 to 28)
NT-proBNP (pg/mL) 1,109 (325 to 2,542) -828 (2,262 to 606) 1,936 (179 to 4,052) 140 (828 to 1,108)
CRP (mg/dL) -3.3 (6.6 to 0.1) -2.5 (5.7 to 0.7) -0.8 (5.6 to 3.9) -2.9 (5.1 to 0.7)
eGFR (mL min1 1.73 m2) -1.7 (14 to 11) -8.6 (22 to 4.4) 6.8 (12 to 26) -5.2 (13 to 3.6)
SDNN, standard deviation of normal to normal intervals; other abbreviations as in Table 1.
Values are presented as marginal mean (95% confidence interval) n 5 28 left and 29 right except 28 right for blood levels and SDNN; 3 missing for all
measurements owing to death.
*Regression coefficient (95% confidence interval) adjusted for baseline values of change variable, history of ischemic etiology, heart rate and heart failure
medications, including angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, loop diuretic, spironolactone, and digoxin (all were on a
beta-blocker).
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mean increase in walk distance was 56 meters (95% CI
37e75). MLHFQ score in the pooled sample improved
by 18 points (95% CI -21 to -16) with little difference be-
tween left- and right-side VNS.Discussion
Safety, Feasibility, and Tolerability
The implementation of ART evaluated in the ANTHEM-
HF study (open loop, low intensity, natural frequency) was
feasible and well tolerated in this study population. No sub-
jects were lost to follow-up or intentionally withdrew from
the study.
The therapy-related nonserious AEs observed in the
ANTHEM-HF study are consistent with those reported in
the epilepsy population.11,12 In all cases, stimulation pa-
rameters were programmed to avoid side effects; however,
during the VNS titration phase, some patients did experi-
ence mild stimulation-related effects which could be
ameliorated with parameter adjustment and subsided over
time. Vagus nerve stimulation on the left side is a well es-
tablished therapy in refractory epilepsy, with a total of
O100,000 device implantations, and has an excellent safety
profile11,12; the results of the present study suggest that a
similar therapy in HF, on either the left or the right side,
would have a similar safety profile.
One device-related SAE was observed. This subject
failed to regain consciousness after the implantation proce-
dure involving the left vagus nerve. The patient had a
history of carotid atherosclerosis and bilateral claudication,
and subsequent computerized tomographic imaging
revealed a nonhemorrhagic brain infarct in the left hemi-
sphere. ARTwas not activated during or after the implanta-
tion procedure. The subject died on the 3rd day after
implantation of the ART system. It is possible that manip-
ulation of the common carotid artery in the neck during
dissection of the vagus nerve caused plaque disruption or
dislodged a thrombus. Careful selection of patients andavoidance of the procedure in patients with severe obstruc-
tive carotid disease is likely to minimize such occurrences.
Efficacy
In the overall combined cohort, there was significant
improvement in LVEF; whereas improvement in LVESV
was not statistically significant. There were also
improvement in LVESD, HR variability, and hs-CRP.
NT-proBNP did not show a statistically significant change,
although the measurement may have been too variable to
detect any changes. All subjective efficacy measures,
including NYHA functional class, 6-minute walk distance,
and MLHFQ scores, showed statistically significant
improvements.
No statistically significant differences between left- and
right-side VNS stimulation were observed in most objective
and subjective efficacy criteria; however, the CIs were wide
and inconclusive. There were consistent trends in most
measures that appeared to favor right- compared with
left-side VNS. However, a larger study is needed to deter-
mine whether right-side VNS may actually produce more
favorable patient outcomes.
Autonomic Regulation Therapy
Early work examining VNS as a cardiovascular therapy
focused on its effects on the sinus node.29 It was thought
that VNS provided a cardiac benefit primarily by slowing
HR and allowing for more effective ventricular filling and
improved pumping efficiency. However, recent studies
have shown that ART at low levels, below what is necessary
to induce an acute decrease in HR, has beneficial
effects.24,30 Experimental data increasingly suggests that
the beneficial effects of ART derive from multiple
mechanisms in which VNS improves regulatory control
of the autonomic nervous system: VNS inhibits neural
release of norepinephrine at cardiac effectors,31 restores
autonomic balance (as reflected in improvements in HR
variability and baroreflex sensitivity),19,21 reduces
systemic inflammation,32e34 increases coronary flow,35
814 Journal of Cardiac Failure Vol. 20 No. 11 November 2014exerts antiapoptotic effects,19,36 and directly modulates
reflex processing within peripheral ganglia of the cardiac
nervous system.38 In addition, ART therapy has been shown
to have antiarrhythmic effects.7e9,14e16
In a recent proof-of-concept open-label phase 2 safety
and feasibility trial, De Ferrari et al21 studied 32 NYHA
functional class IIeIV HFrEF patients. The right cervical
vagus nerve was stimulated with the Cardiofit system
(Biocontrol Medical, Yehud, Israel), which uses an intracar-
diac sensing lead to synchronize high-amplitude VNS
pulses with the cardiac cycle in an attempt to induce a
mild bradycardia, an approach which the results of the
ANTHEM-HF study suggest may be unnecessary to yield
a clinical benefit. The De Ferrari et al study found that
VNS was associated with a significant improvement in
LVEF, LVESV, NYHA functional class, quality of life,
and 6-minute walk distance at 6 months, and that those im-
provements were maintained at 12 months. Despite using a
lower intensity of stimulation (a mean of 2.0 mA compared
with a mean of 4.1 mA), the magnitude of improvements in
efficacy measurements seen in ANTHEM-HF is similar to
those reported by De Ferrari et al. These similarities may
be due to the use of a higher stimulation frequency
(10 Hz) in the present study.
Furthermore, De Ferrari et al reported a total of 26 SAEs
over 6 months, including 3 deaths, with 7 SAEs (22%) defi-
nitely or possibly related to the therapy. The incidence of
therapy-related SAEs in ANTHEM-HF (1 event, 1.7%)
was much lower. The most common nonserious AEs re-
ported by De Ferrari et al were mild pain, cough, and
dysphonia, as seen in ANTHEM-HF. The Cardiofit system
is now being evaluated in a 650-patient phase III trial,
the Increase of Vagal Tone in Chronic Heart Failure
(INOVATE-HF) study.22
ART is also being studied in a 96-patient phase II study
sponsored by Boston Scientific (St Paul, Minnesota), the
Neurocardiac Therapy for Heart Failure (NECTAR-HF)
study.23 In NECTAR-HF, as in ANTHEM-HF, low-ampli-
tude stimulation is not synchronized with the cardiac cycle;
however, the Boston Scientific VNS system uses a substan-
tially higher stimulation frequency (20 Hz). Interestingly,
chronic VNS at 10 Hz frequency (near the natural fre-
quency of discharge of vagal fibers during reflex activa-
tion27,39,40), but not 5 Hz or 20 Hz, has been shown to
reduce mean HR and increase HR variability over a 24-
hour period.37 As in INOVATE-HF, the NECTAR-HF study
is evaluating ART restricted to the right vagus nerve.
ANTHEM-HF is the first clinical study to compare the
feasibility and tolerance of left- and right-side ART, and
to compare safety and efficacy measures. ART applied to
either left or right cervical vagus nerve for the treatment
of HFrEF appears to be both feasible and tolerable. Preclin-
ical studies have demonstrated that ART engages multiple
levels of the autonomic reflex hierarchy for cardiac control
via its activation of both afferent and efferent projections of
the vagus nerve.41 Regardless of which vagus nerve is stim-
ulated, left or right, it seems likely that cardiac and centraleffects are elicited, reflecting the interplay between central
and peripheral aspects of the cardiac nervous system.
Anatomically, both right and left vagus nerves show sub-
stantial projections to all chambers of the heart, as mediated
by multiple ganglionated plexi of the intrinsic cardiac ner-
vous system.42,43
Although some outcome measures show a trend toward
greater efficacy with right-side stimulation, the data do
not support the conclusion that ART applied to the right
or left vagus nerve yields significantly different efficacy re-
sults, and further evaluation is required.
Study Limitations
In this modest-size study, the CIs of the estimated differ-
ences between left- and right-side VNS were wide and
could not rule out clinically important differences. The
overall effects seen in this uncontrolled study cannot be
solely attributed to the ART. It is possible that at least
some of the clinical improvements are due to the placebo
effect, especially in the more subjective assessments.
Nevertheless, the overall directional change in all measured
study parameters shown after 6 months of therapy is
encouraging and sufficient to justify a randomized
controlled study. The ANTHEM-HF study was conducted
at clinical centers in India, and the results may not be gener-
alizable to other populations.
Conclusion
The results of the ANTHEM-HF study demonstrate that
ART with the use of chronic low-amplitude VNS, on either
the left or the right side, is feasible and well tolerated in pa-
tients with HFrEF. No unexpected AEs were observed. The
preliminary assessment of efficacy measures is promising,
and reveals that outcomes may be more favorable with
right-side VNS; however, this needs to be confirmed in a
larger controlled trial. Further investigation of the safety
and efficacy of this therapy in a controlled clinical study
is warranted.
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